Detection of Bordetella pertussis and Bordetella parapertussis using molecular methods is sensitive and specific with a short turnaround time compared to other diagnostic methods. In this multicenter study, we compared the performance of the Simplexa Bordetella Direct kit to those of other molecular assays in detecting and differentiating B. pertussis and B. parapertussis in nasopharyngeal swab specimens. The limits of detection (LODs) were 150 CFU/ml or 3 fg/μl of DNA for B. pertussis and 1,500 CFU/ml or 10 fg/μl of DNA for B. parapertussis. A total of 1,103 fresh and residual frozen specimens from eight clinical sites were tested. Combining the data from individual clinical sites using different comparative assays, the overall positive percent agreement (PPA) and negative percent agreement (NPA) for B. pertussis were 98.7% and 97.3%, respectively. The overall PPA and NPA for B. parapertussis were 96.7% and 100%, respectively. For prospective fresh specimens, the overall PPA and NPA for both targets were 97.7% and 99.3%, respectively. For retrospective frozen specimens, the overall PPA and NPA for both targets were 92.6% and 93.2%, respectively. The percentage of invalid results was 1.0%. A cross-reactivity study using 74 non-Bordetella bacterial species and five yeast species revealed that the Simplexa Bordetella Direct kit was 100% specific. The hands-on time and assay run time of the Simplexa Bordetella Direct kit are favorable compared to those of other commercial and laboratory-developed tests. In summary, the Simplexa Bordetella Direct kit has a performance comparable to those of other molecular assays for the detection of B. pertussis and B. parapertussis.
Bibliographical noteFunding Information:
This study was supported by DiaSorin Molecular.
This study was supported by DiaSorin Molecular. S.-K.C. thanks the microbiology team at MultiCare Health System for their technical support. P.F. and S.A. thank Ann Fickle and Elizabeth Thonen-Kerr from the University of Minnesota Medical Center and Fairview Health System Infectious Diseases Diagnostic Laboratory for their technical expertise. B.L.B. thanks Ann Prada at Beaumont Health for her technical assistance. T.E.S. thanks Tong Her at Ascension St. John Hospital for his technical assistance. S.R. has been an employee of bioM?rieux since 12 August 2019. When employed at Cleveland Clinic, she received research funding from bioM?rieux, BD Diagnostics, Roche, DiaSorin, Accelerate, and Affinity Biosensors. All other authors have no conflict.
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
- Bordetella species
- Turnaround time
- Whooping cough
PubMed: MeSH publication types
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't